Who Owns Monogram Technologies?
Monogram Technologies is owned by Zimmer Biomet Holdings (NYSE and SIX: ZBH), a publicly traded medical technology company headquartered in Warsaw, Indiana. Monogram was incorporated in Delaware on April 21, 2016, and was headquartered in Austin, Texas. Zimmer Biomet announced the acquisition on July 14, 2025, for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million. Monogram developed the mBos surgical robotic system for total knee arthroplasty, which received FDA 510(k) clearance in March 2025.
Parent Company
Acquired
2025
Status
Publicly Traded
Headquarters
Monogram Technologies Timeline
Who Owns Monogram Technologies?
- Parent Company: Zimmer Biomet Holdings, Inc.
- Ownership Type: Wholly owned
- Acquisition Year: 2025
- Company Type: Publicly Traded
- Stock Ticker: NYSE: ZBH
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Monogram Technologies | Zimmer Biomet Holdings, Inc. | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Monogram Technologies on AmazonHistory of Monogram Technologies
- Founded: 2016
- Founders: Benjamin Sexson
- Acquired by Zimmer Biomet Holdings, Inc.: 2025
Monogram Technologies was incorporated in Delaware on April 21, 2016, originally under the name Monogram Orthopaedics Inc. The company was founded as an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. Monogram's headquarters were in Austin, Texas.
The company conducted its first cadaver lab in 2019, testing its robotic surgical technology for orthopedic procedures. Monogram's core technology is the mBos surgical robotic system, a CT-based, semi-autonomous, AI-navigated robotic platform for total knee arthroplasty (TKA). The system uses CT scans to help plan bone cuts in advance and establishes instrument boundaries to avoid damage to the joint's soft tissue.
In March 2025, Monogram received FDA 510(k) clearance for the mBos system for total knee replacement surgeries, as well as for its mPress 3D-printed, press-fit implants. The company also received approval in India to conduct a clinical trial of its hands-free robotic saw, with its first live human procedures conducted in summer 2025.
On May 15, 2024, the company changed its name from Monogram Orthopaedics Inc. to Monogram Technologies Inc. CEO Benjamin Sexson stated that the name change reflected the company's evolution since 2016 and the broadening applications for its technology. The company's common stock continued to trade on NASDAQ under the symbol MGRM.
On July 14, 2025, Zimmer Biomet announced the definitive agreement to acquire Monogram Technologies. Zimmer Biomet CEO Ivan Tornos stated that the acquisition would give Zimmer Biomet "the most comprehensive and flexible technology ecosystem" to support surgeons' varying preferences and the potential to become the first company to deliver fully autonomous surgical capabilities in orthopedics. The transaction was expected to close by the end of 2025, subject to regulatory approval and Monogram shareholder approval.
Monogram is also developing a fully autonomous version of its robotic technology, which would allow the robot to execute bone cuts without surgeon manual control, operated by foot pedal. This technology has the potential to significantly increase safety, efficiency, and outcomes in orthopedic surgery.
About Zimmer Biomet Holdings, Inc.
Is Zimmer Biomet publicly traded?
Yes. Zimmer Biomet Holdings, Inc. trades on the New York Stock Exchange under the ticker symbol ZBH. The company is also listed on the SIX Swiss Exchange. Zimmer Biomet is a component of the S&P 500 index. The company was first spun off from Bristol Myers Squibb in August 2001 and has been independently traded since then.
When was Zimmer Biomet founded?
Zimmer Biomet traces its origins to 1927, when Justin O. Zimmer founded Zimmer Manufacturing Company in Warsaw, Indiana, to produce aluminum splints. The modern Zimmer Biomet Holdings, Inc. was incorporated in Delaware in 2001 and was formed through the acquisition of Biomet, Inc. in June 2015, at which point the company changed its name from Zimmer Holdings, Inc. to Zimmer Biomet Holdings, Inc.
Where is Zimmer Biomet headquartered?
Zimmer Biomet is headquartered at 345 East Main Street, Warsaw, Indiana 46580, USA. Warsaw, Indiana, is a major hub for the orthopedic device industry, with Zimmer Biomet as one of its anchor companies. The company operates manufacturing and distribution facilities across the United States, Europe, Asia, and Latin America.
What products does Zimmer Biomet make?
Zimmer Biomet manufactures orthopedic reconstructive products (knee, hip, shoulder, elbow replacements), sports medicine and biologics products, extremities and trauma products, craniomaxillofacial and thoracic products, bone cement, surgical products, and integrated digital and robotic technologies. Key product platforms include ROSA Robotic Solutions, Persona OsseoTi Keel Tibia, Oxford Cementless Partial Knee, Z1 Femoral Hip System, and iTaperloc Complete and iG7 Hip System with iodine-treated implants.
What are Zimmer Biomet's major acquisitions?
Zimmer Biomet's most significant acquisition was Biomet, Inc. in June 2015 for approximately $14.0 billion, which created the current company. Other major acquisitions include Centerpulse AG (2003, $3.2 billion), LDR Holding Corporation (2016, $1 billion), Paragon 28 (April 2025, $1.2 billion), OrthoGrid Systems (2024), Monogram Technologies (2025), and the iovera pain therapy business from Pacira BioSciences (2026, $140 million).
What is ZimVie?
ZimVie Inc. (NASDAQ: ZVIE) is an independent public company that was spun off from Zimmer Biomet in March 2022. ZimVie operates Zimmer Biomet's former spine and dental business. The spin-off allowed Zimmer Biomet to focus on its core orthopedic reconstructive and sports medicine businesses. ZimVie is no longer part of Zimmer Biomet.
Who is the CEO of Zimmer Biomet?
Ivan Tornos serves as Chairman, President, and CEO of Zimmer Biomet. Tornos was appointed CEO in 2023, succeeding Bryan Hanson. Under Tornos's leadership, the company has focused on its "Magnificent Seven" innovation platforms, completed three transformative acquisitions, and initiated a transition to a direct sales model in the U.S.
What is Zimmer Biomet's revenue?
Zimmer Biomet reported FY2025 (ended December 31, 2025) net sales of $8.23 billion, up 7.2% from $7.68 billion in FY2024. Net earnings were $705.1 million, and adjusted net earnings were $1.63 billion. Diluted EPS was $3.55, and adjusted diluted EPS was $8.20. For Q1 2026, net sales were $2.09 billion, up 9.3%, with net earnings of $238.1 million and diluted EPS of $1.22.
- Founded: 1927
- Headquarters: Warsaw, Indiana, USA
- Company Type: Publicly Traded
- Stock: NYSE: ZBH
- Revenue: $8.23 billion (FY2025, ended December 2025)
- Employees: ~17,000
Where Is Monogram Technologies Made / Based?
- Headquarters: Austin, Texas, USA
- Manufacturing / Operations: United States
Monogram Technologies Categories & Tags
Monogram Technologies Sustainability & Ethics
Monogram Technologies' sustainability profile is tied to Zimmer Biomet's corporate environmental and ethics programs. As a pre-revenue medical device company at the time of acquisition, Monogram did not have independent sustainability reporting or certifications.
Zimmer Biomet reports on environmental, social, and governance (ESG) performance at the corporate level. The company's ESG initiatives include environmental compliance across manufacturing operations, ethical business practices in medical device marketing and sales, and responsible sourcing of materials.
As a medical device company, Monogram's primary ethical considerations relate to patient safety, regulatory compliance, and product quality. The mBos system received FDA 510(k) clearance in March 2025, demonstrating compliance with U.S. medical device safety and effectiveness requirements. Monogram also received approval in India to conduct clinical trials of its hands-free robotic saw.
No independent third-party sustainability certifications specific to Monogram Technologies were identified as of August 2026.
Awards & Recognition
Monogram Technologies' recognition comes primarily from its FDA clearances and industry coverage of its robotic technology, rather than from traditional industry awards.
Monogram received FDA 510(k) clearance for its mBos surgical robotic system for total knee arthroplasty in March 2025. This clearance represented a significant regulatory milestone, allowing the company to market the system in the United States. The company also received FDA 510(k) clearance for its mPress 3D-printed, press-fit implants.
Monogram received approval in India to conduct a clinical trial of its hands-free robotic saw, with first live human procedures conducted in summer 2025. This represented a milestone in the development of fully autonomous orthopedic surgical robotics.
The acquisition by Zimmer Biomet, valued at approximately $177 million in equity value with up to $12.37 per share in CVR milestones, represents market recognition of Monogram's technology and its potential to advance orthopedic surgical robotics.
No independent consumer publication awards or traditional industry product awards specific to Monogram Technologies were identified as of August 2026.
Monogram Technologies Recalls & Controversies
No major product safety recalls specific to Monogram Technologies were identified as of August 2026. The mBos system received FDA 510(k) clearance in March 2025, and the product is not yet commercially launched, with commercialization expected in early 2027.
Monogram Technologies was a pre-revenue company at the time of the Zimmer Biomet acquisition. According to SEC filings, the company had not yet generated significant revenue from product sales and was focused on research and development, regulatory clearances, and clinical trials. The company's financial position required ongoing capital raises, which led to its listing on NASDAQ and eventual acquisition by Zimmer Biomet.
The acquisition itself was subject to regulatory scrutiny and required approval from Monogram shareholders and regulatory authorities. The transaction was expected to close by the end of 2025.
No Monogram Technologies-branded product safety recalls were identified as of August 2026.
Brands Owned by Zimmer Biomet Holdings, Inc.
Monogram Technologies Ownership: Pros & Cons
Advantages
- +Access to Zimmer Biomet's global distribution network spanning more than 100 countries
- +Integration with Zimmer Biomet's ROSA Robotics platform, which is approaching 2,000 installations worldwide
- +Zimmer Biomet's $8.23 billion in 2025 net sales and $1.17 billion in free cash flow provide financial resources for R&D and commercialization
- +Pathway to become the first company in orthopedics to offer a fully autonomous surgical robot
- +Commercial launch with Zimmer Biomet implants expected in early 2027, providing a clear revenue timeline
- +CVR structure provides up to $12.37 per share in additional consideration tied to milestones through 2030
Considerations
- -The mBos system is not yet commercialized, with launch expected in early 2027
- -The acquisition is expected to be neutral to adjusted EPS through 2027 and accretive only thereafter
- -Monogram's technology faces competition from Stryker (Mako), Medtronic (Mazor X), Johnson & Johnson (Velys), and Globus Medical (ExcelsiusGPS)
- -Regulatory approvals are required for additional applications beyond total knee arthroplasty
- -The fully autonomous version of the technology is still in development
- -Dependency on Zimmer Biomet's corporate strategy and resource allocation
Frequently Asked Questions About Monogram Technologies
Sources & Further Reading
- Zimmer Biomet Acquisition Announcement (July 14, 2025)
- Reuters, Zimmer to Acquire Monogram Technologies
- MedTech Dive, Zimmer to Buy Robotics Firm Monogram
- Fierce Biotech, Zimmer Biomet Inks $177M Deal for Monogram
- Zimmer Biomet Q4 and Full-Year 2025 Financial Results (February 10, 2026)
- Zimmer Biomet 10-K Annual Report (SEC Filing)
- Zimmer Biomet 2025 Annual Report
- Monogram Technologies Official Website
- Monogram Technologies Company Page
- Monogram Technologies SEC Filing (Name Change, May 2024)
- Zimmer Biomet Investor Relations
- FDA Medical Device Database
Competitors to Monogram Technologies
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Zimmer Biomet | USA | 2010 | Mass market | Global | All Genders |
Competitive Analysis
Market Positioning: Monogram Technologies competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Monogram Technologies
Looking for brands with different ownership structures? These similar brands are not owned by Zimmer Biomet Holdings, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsGE HealthCare
Owned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
healthcare-technologymedical-imagingdiagnostics
Publicly Traded
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsPhilips
Owned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
healthcare-technologyelectronicsmedical-devices
Publicly Traded
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Publicly Traded
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Monogram Technologies which is under a publicly traded parent company.
Healthcare PharmaceuticalsAlcon
Owned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
eye-carecontact-lensesophthalmic
Publicly Traded
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsHerbalife
Owned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
nutritiondietary-supplementsweight-management
Publicly Traded
Herbalife operates independently without a large parent corporation.
Zimmer Biomet Holdings, Inc. Stock Information
Jobs at Zimmer Biomet Holdings, Inc.
Latest News About Monogram Technologies
Related Articles About Monogram Technologies
View more articles
Entertainment
Toy Brand Ownership: From LEGO to Hasbro
LEGO is family-owned by the Kirk Kristiansens. Hasbro and Mattel are Wall Street-owned. Bandai Namco owns Tamagotchi. Discover who owns the biggest toy brands and why it matters. Explore our database.
Who Brands StaffSep 4, 2026
ToysLegoHasbro
Pop Culture
Video Game Brands and Their Corporate Parents
EA sold for $55B to Saudi Arabia's PIF, Silver Lake and Kushner's Affinity. Microsoft bought Activision Blizzard for $75.4B. Tencent owns Riot, Supercell, and stakes in Epic. Sony bought Bungie for $3.6B. Discover video game brands and their corporate parents.
Who Brands StaffSep 3, 2026
Video GamesAcquisitionsEa
Pop Culture
Brands That Appeared in Super Bowl Ads Then Got Acquired
Poppi ran a Super Bowl ad in February 2025 and PepsiCo bought it for $1.95B. Grubhub debuted in Super Bowl LX after Wonder acquired it for $650M. WeatherTech ran its 14th ad. Discover brands that appeared in Super Bowl ads then got acquired.
Who Brands StaffSep 2, 2026
Super BowlAcquisitionsPoppi
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Brandpharmaceutical
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment